Inhibition of RET activated pathways: Novel strategies for therapeutic intervention in human cancers

Libero Santarpia, Giulia Bottai

Research output: Contribution to journalArticlepeer-review


The REarranged during Transfection (RET) proto-oncogene and its activated signalling pathways have been shown to play an important role in cancer. RET genetic alterations including germline, somatic mutations and gene rearrangements have been demonstrated in several solid tumours, and numerous clinical trials using multikinase inhibitors containing RET as a target have shown significant activity against RET. Sorafenib and sunitinib have been approved for the treatment of renal, hepatocellular, gastrointestinal and pancreatic neuoendocrine carcinomas. Vandetanib has recently been approved for the treatment of unresectable locally advanced or metastatic medullary thyroid carcinomas. Novel genomic rearrangements and RET signalling interactions are now being studied in a variety of tumours and will provide the basis for new therapeutic strategies. Combination or sequential targeted therapies that are based on solid preclinical data regarding the inhibition of RET-mediated parallel or different -signalling pathways will likely be more effective.

Original languageEnglish
Pages (from-to)864-882
Number of pages19
JournalCurrent Pharmaceutical Design
Issue number5
Publication statusPublished - 2013


  • Cancer
  • Clinical trials
  • RET interacting proteins
  • RET proto-oncogene
  • RET-activated signalling pathways
  • Targeted therapies
  • Therapeutic strategies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Inhibition of RET activated pathways: Novel strategies for therapeutic intervention in human cancers'. Together they form a unique fingerprint.

Cite this